x
|
QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Nevada
|
94-3355026
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
Registrant’s
telephone number, including area code:
|
(604)
687-9887
|
|
Securities
registered pursuant to Section 12(b) of the Act:
|
None
|
|
Securities
registered pursuant to Section 12(g) of the Act:
|
$.0000053
par value common stock
|
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨
|
Smaller
reporting company x
|
ITEM
1.
|
FINANCIAL
STATEMENTS
|
PROTOKINETIX,
INC.
|
|
June
30,
2008
|
December
31, 2007
|
|||||||
ASSETS
|
||||||||
Current
Assets
|
||||||||
Cash
|
$ | 77,785 | $ | 37,350 | ||||
Prepaid
expenses
|
427,500 | 110,000 | ||||||
Total
current assets
|
505,285 | 147,350 | ||||||
Computer
equipment, net of accumulated depreciation of $2,963 and $3,388 at
December 31, 2007 and June 30, 2008 respectively
|
- | 426 | ||||||
$ | 505,285 | $ | 147,776 | |||||
LIABILITIES
AND STOCKHOLDERS' EQUITY (DEFICIT)
|
||||||||
Current
Liabilities
|
||||||||
Accounts
payable
|
$ | 428 | $ | 108,825 | ||||
Convertible
note payable
|
300,000 | 300,000 | ||||||
Total
Liabilities
|
300,428 | 408,825 | ||||||
Stockholders'
Equity (Deficit)
|
||||||||
Common
stock, $.0000053 par value; 100,000,000 common shares authorized;
52,781,958 and 48,444,442 shares issued and outstanding at June
30, 2008 at December 31, 2007, respectively
|
284 | 262 | ||||||
Common
stock issuable; 2,850,000 and 1,190,000 shares at June 30, 2008
and December 31, 2007, respectively
|
14 | 6 | ||||||
Additional
paid-in capital
|
20,743,685 | 19,323,715 | ||||||
Deficit
accumulated during the development stage
|
(20,539,126 | ) | (19,585,032 | ) | ||||
204,857 | (261,049 | ) | ||||||
$ | 505,285 | $ | 147,776 |
Three
Months Ended
June
30, 2008
|
Three
Months Ended
June
30, 2007
|
Six
Months Ended
June
30, 2008
|
Six
Months Ended
June
30, 2007
|
Cumulative
During the Development Stage
|
||||||||||||||||
Revenues
|
$ | - | $ | - | $ | - | $ | - | $ | 2,000 | ||||||||||
General
and administrative expenses
|
||||||||||||||||||||
Licenses
|
3,379,756 | |||||||||||||||||||
Professional
fees
|
21,863 | 85,132 | 97,011 | 167,132 | 3,328,523 | |||||||||||||||
Consulting
fees
|
277,593 | 55,000 | 392,593 | 165,000 | 10,760,672 | |||||||||||||||
Research
and development
|
207,024 | 81,503 | 302,226 | 141,503 | 2,099,655 | |||||||||||||||
General
and Administrative
|
102,841 | 38,585 | 150,264 | 72,951 | 856,892 | |||||||||||||||
Interest
|
6,000 | - | 12,000 | - | 72,162 | |||||||||||||||
615,321 | 260,220 | 954,094 | 546,586 | 20,497,660 | ||||||||||||||||
Loss
from continuing operations
|
(615,321 | ) | (260,220 | ) | (954,094 | ) | (546,586 | ) | (20,495,660 | ) | ||||||||||
Discontinued
Operations
|
||||||||||||||||||||
Loss
from operations of the discontinued segment
|
- | - | (43,466 | ) | ||||||||||||||||
Net
loss
|
$ | (615,321 | ) | $ | (260,220 | ) | $ | (954,094 | ) | $ | (546,586 | ) | $ | (20,539,126 | ) | |||||
Net
Loss per Share (basic and fully diluted)
|
||||||||||||||||||||
Continuing
operations
|
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.01 | ) | ||||||||
Discontinued
operations
|
0.00 | (0.00 | ) | (0.00 | ) | (0.00 | ) | |||||||||||||
Net
loss per common share
|
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.01 | ) | ||||||||
Weighted
average shares outstanding
|
52,520,628 | 45,168,662 | 51,292,277 | 45,026,868 |
Deficit
Accumulated
|
||||||||||||||||||||||||||||||||
Common
Stock
|
Additional
|
During
the
|
||||||||||||||||||||||||||||||
Common
Stock
|
Issuable
|
Paid-in
|
Subscription
|
Development
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Receivable
|
Stage
|
Total
|
|||||||||||||||||||||||||
Issuance
of common stock, December 1999
|
9,375,000 | $ | 50 | - | $ | - | $ | 4,950 | $ | - | $ | - | $ | 5,000 | ||||||||||||||||||
Net
loss for period
|
(35 | ) | (35 | ) | ||||||||||||||||||||||||||||
Balance,
December 31, 2000
|
9,375,000 | 50 | - | - | 4,950 | (35 | ) | 4,965 | ||||||||||||||||||||||||
Issuance
of common stock, April 2001
|
5,718,750 | 30 | 15,220 | 15,250 | ||||||||||||||||||||||||||||
Net
loss for year
|
(16,902 | ) | (16,902 | ) | ||||||||||||||||||||||||||||
Balance,
December 31, 2001
|
15,093,750 | 80 | - | - | 20,170 | (16,937 | ) | 3,313 | ||||||||||||||||||||||||
Net
loss for year
|
(14,878 | ) | (14,878 | ) | ||||||||||||||||||||||||||||
Balance,
December 31, 2002
|
15,093,750 | 80 | - | - | 20,170 | (31,815 | ) | (11,565 | ) | |||||||||||||||||||||||
Issuance
of common stock for services:
|
||||||||||||||||||||||||||||||||
July
2003
|
2,125,000 | 11 | 424,989 | 425,000 | ||||||||||||||||||||||||||||
August
2003
|
300,000 | 2 | 14,998 | 15,000 | ||||||||||||||||||||||||||||
September
2003
|
1,000,000 | 5 | 49,995 | 50,000 | ||||||||||||||||||||||||||||
October
2003
|
1,550,000 | 8 | 619,992 | 620,000 | ||||||||||||||||||||||||||||
Issuance
of common stock for licensing rights
|
14,000,000 | 74 | 2,099,926 | 2,100,000 | ||||||||||||||||||||||||||||
Common
stock issuable for licensing rights
|
2,000,000 | 11 | 299,989 | 300,000 | ||||||||||||||||||||||||||||
Shares
cancelled on September 30, 2003
|
(9,325,000 | ) | (49 | ) | 49 | - | ||||||||||||||||||||||||||
Net
loss for year
|
(3,662,745 | ) | (3,662,745 | ) |
Deficit
Accumulated
|
||||||||||||||||||||||||||||||||
Common
Stock
|
Additional
|
During
the
|
||||||||||||||||||||||||||||||
Common
Stock
|
Issuable
|
Paid-in
|
Subscription
|
Development
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Receivable
|
Stage
|
Total
|
|||||||||||||||||||||||||
Balance,
December 31, 2003
|
24,743,750 | 131 | 2,000,000 | 11 | 3,530,108 | - | (3,694,560 | ) | (164,310 | ) | ||||||||||||||||||||||
Issuance
of common stock for services:
|
||||||||||||||||||||||||||||||||
March
2004
|
1,652,300 | 9 | 991,371 | 991,380 | ||||||||||||||||||||||||||||
May
2004
|
500,000 | 3 | 514,997 | 515,000 | ||||||||||||||||||||||||||||
July
2004
|
159,756 | 1 | 119,694 | 119,695 | ||||||||||||||||||||||||||||
August
2004
|
100,000 | 1 | 70,999 | 71,000 | ||||||||||||||||||||||||||||
October
2004
|
732,400 | 4 | 479,996 | 480,000 | ||||||||||||||||||||||||||||
November
2004
|
650,000 | 4 | 454,996 | 455,000 | ||||||||||||||||||||||||||||
December
2004
|
255,000 | 1 | 164,425 | 164,426 | ||||||||||||||||||||||||||||
Common
stock issuable for AFGP license
|
1,000,000 | 5 | 709,995 | 710,000 | ||||||||||||||||||||||||||||
Common
stock issuable for Recaf License
|
400,000 | 2 | 223,998 | 224,000 | ||||||||||||||||||||||||||||
Warrants
granted (for 3,450,000 shares) for services,
|
||||||||||||||||||||||||||||||||
October
2004
|
1,716,253 | 1,716,253 | ||||||||||||||||||||||||||||||
Options
granted for services, October 2004
|
212,734 | 212,734 | ||||||||||||||||||||||||||||||
Stock
subscriptions receivable
|
1,800,000 | 10 | 329,990 | (330,000 | ) | - | ||||||||||||||||||||||||||
Warrants
exercised:
|
- | |||||||||||||||||||||||||||||||
August
2004
|
50,000 | 15,000 | 15,000 | |||||||||||||||||||||||||||||
October
2004
|
600,000 | 3 | 134,997 | 135,000 | ||||||||||||||||||||||||||||
December
2004
|
1,000,000 | 5 | 224,995 | 225,000 | ||||||||||||||||||||||||||||
Options
exercised, December 2004
|
100,000 | 1 | 29,999 | 30,000 | ||||||||||||||||||||||||||||
Net
loss for period
|
(6,368,030 | ) | (6,368,030 | ) | ||||||||||||||||||||||||||||
Balance,
December 31, 2004
|
28,793,206 | $ | 154 | 6,950,000 | $ | 37 | $ | 9,924,547 | $ | (330,000 | ) | (10,062,590 | ) | $ | (467,852 | ) |
Deficit
Accumulated
|
||||||||||||||||||||||||||||||||
Common
Stock
|
Additional
|
During
the
|
||||||||||||||||||||||||||||||
Common
Stock
|
Issuable
|
Paid-in
|
Subscription
|
Development
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Receivable
|
Stage
|
Total
|
|||||||||||||||||||||||||
Issuance
of stock subscriptions receivable
|
$ | 240,000 | 240,000 | |||||||||||||||||||||||||||||
Issuance
of common stock for licensing rights
|
2,000,000 | 11 | (2,000,000 | ) | (11 | ) | - | |||||||||||||||||||||||||
Issuance
of stock for warrants exercised
|
2,050,000 | 10 | (2,050,000 | ) | (10 | ) | - | |||||||||||||||||||||||||
Options
exercised,
|
||||||||||||||||||||||||||||||||
February
2005
|
35,000 | 1 | 10,499 | 10,500 | ||||||||||||||||||||||||||||
May
2005
|
200,000 | 1 | 59,999 | 60,000 | ||||||||||||||||||||||||||||
Note
payable conversion, February 2005
|
285,832 | 1 | 85,749 | 85,750 | ||||||||||||||||||||||||||||
Issuance
of common stock for Note payable conversion
|
||||||||||||||||||||||||||||||||
April
2005
|
285,832 | 1 | (285,832 | ) | (1 | ) | - | |||||||||||||||||||||||||
May
2005
|
353,090 | 2 | 105,925 | 105,927 | ||||||||||||||||||||||||||||
Issuance
of common stock for AFGP license
|
1,000,000 | 5 | (1,000,000 | ) | (5 | ) | - | |||||||||||||||||||||||||
Issuance
of common stock for stock subscriptions received
|
1,400,000 | 6 | (1,400,000 | ) | (6 | ) | 90,000 | 90,000 | ||||||||||||||||||||||||
Issuance
of stock for options exercised
|
135,000 | 2 | (135,000 | ) | (2 | ) | - | |||||||||||||||||||||||||
Issuance
of common stock for services:
|
||||||||||||||||||||||||||||||||
April
2005
|
30,000 | 1 | 14,999 | 15,000 | ||||||||||||||||||||||||||||
May
2005
|
3,075,000 | 15 | 3,320,985 | 3,321,000 | ||||||||||||||||||||||||||||
June
2005
|
50,000 | 1 | 50,499 | 50,500 | ||||||||||||||||||||||||||||
August
2005
|
(250,000 | ) | (1 | ) | (257,499 | ) | (257,500 | ) | ||||||||||||||||||||||||
August
2005
|
111,111 | 1 | (92,593 | ) | (1 | ) | 15,000 | 15,000 | ||||||||||||||||||||||||
October
2005
|
36,233 | 1 | (36,233 | ) | (1 | ) | - | - | ||||||||||||||||||||||||
November
2005
|
||||||||||||||||||||||||||||||||
November
2005
|
311,725 | 2 | (245,000 | ) | (1 | ) | 36,249 | 36,250 | ||||||||||||||||||||||||
December
2005
|
1,220,000 | 8 | 756,392 | 756,400 |
Deficit
Accumulated
|
||||||||||||||||||||||||||||||||
Common
Stock
|
Additional
|
During
the
|
||||||||||||||||||||||||||||||
Common
Stock
|
Issuable
|
Paid-in
|
Subscription
|
Development
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Receivable
|
Stage
|
Total
|
|||||||||||||||||||||||||
Common
stock issuable for services rendered
|
||||||||||||||||||||||||||||||||
June
2005
|
200,000 | 1 | 149,999 | 150,000 | ||||||||||||||||||||||||||||
August
2005
|
36,233 | 1 | 21,739 | 21,740 | ||||||||||||||||||||||||||||
September
2005
|
125,000 | 1 | 74,999 | 75,000 | ||||||||||||||||||||||||||||
September
2005(Proteocell)
|
100,000 | 1 | 57,999 | 58,000 | ||||||||||||||||||||||||||||
December
2005
|
120,968 | 1 | 74,999 | 75,000 | ||||||||||||||||||||||||||||
Net
loss for the year
|
(4,826,540 | ) | (4,826,540 | ) | ||||||||||||||||||||||||||||
Balance,
December 31, 2005
|
40,801,197 | $ | 220 | 608,375 | $ | 6 | $ | 14,503,079 | $ | - | (14,889,130 | ) | $ | (385,825 | ) | |||||||||||||||||
February
2006 private placement (issued June 2006)
|
900,000 | 5 | 352,142 | 352,147 | ||||||||||||||||||||||||||||
Warrants
granted from private placement (450,000)
|
97,853 | 97,853 | ||||||||||||||||||||||||||||||
Issuance
of common stock for Note payable conversion
|
529,279 | 3 | 158,780 | 158,783 | ||||||||||||||||||||||||||||
Issuance
of common stock for services:
|
||||||||||||||||||||||||||||||||
February/March
2006 services
|
20,000 | 1 | 10,499 | 10,500 | ||||||||||||||||||||||||||||
March
2006
|
166,359 | 1 | (108,375 | ) | (1 | ) | 36,750 | 36,750 | ||||||||||||||||||||||||
April
2006
|
(1,200,000 | ) | (6 | ) | 6 | - | ||||||||||||||||||||||||||
May
2006
|
1,266,278 | 7 | (70,000 | ) | (1 | ) | 792,750 | 792,756 | ||||||||||||||||||||||||
June
2006
|
27,056 | 1,200,000 | 6 | 718,244 | 718,250 | |||||||||||||||||||||||||||
July
2006
|
1,200,000 | 6 | (1,200,000 | ) | (6 | ) | - | |||||||||||||||||||||||||
August
2006
|
100,000 | 1 | 64,999 | 65,000 | ||||||||||||||||||||||||||||
September
2006
|
369,984 | 2 | (50,000 | ) | 209,998 | 210,000 | ||||||||||||||||||||||||||
November
2006
|
100,000 | 1 | 48,999 | 49,000 | ||||||||||||||||||||||||||||
December
2006
|
7,000 | 3,010 | 3,010 |
Deficit
Accumulated
|
||||||||||||||||||||||||||||||||
Common
Stock
|
Additional
|
During
the
|
||||||||||||||||||||||||||||||
Common
Stock
|
Issuable
|
Paid-in
|
Subscription
|
Development
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Receivable
|
Stage
|
Total
|
|||||||||||||||||||||||||
Warrants
issued (for 700,000 shares) for services
|
58,658 | 58,658 | ||||||||||||||||||||||||||||||
Net
loss for the period
|
(1,967,633 | ) | (1,967,633 | ) | ||||||||||||||||||||||||||||
Balance,
December 31, 2006
|
44,267,153 | 240 | 400,000 | 5 | 17,055,767 | - | (16,856,763 | ) | 199,249 | |||||||||||||||||||||||
Issuance
of common stock for services:
|
||||||||||||||||||||||||||||||||
January
2007
|
218,834 | 1 | 119,999 | 120,000 | ||||||||||||||||||||||||||||
March
2007
|
104,652 | 1 | 44,999 | 45,000 | ||||||||||||||||||||||||||||
April
2007
|
187,500 | 1 | 74,999 | 75,000 | ||||||||||||||||||||||||||||
June
2007
|
112,500 | 1 | 44,999 | 45,000 | ||||||||||||||||||||||||||||
July
2007
|
291,812 | 2 | 112,998 | 113,000 | ||||||||||||||||||||||||||||
August
2007
|
860,000 | 5 | 257,995 | 258,000 | ||||||||||||||||||||||||||||
Sept
2007
|
1,516,275 | 8 | 457,492 | 457,500 | ||||||||||||||||||||||||||||
Oct
2007
|
250,000 | 1 | 37,499 | 37,500 | ||||||||||||||||||||||||||||
Dec
2007
|
535,716 | 1 | 74,999 | 75,000 | ||||||||||||||||||||||||||||
Warrants
issued for services
|
825,476 | 825,476 | ||||||||||||||||||||||||||||||
Cancellation
of issuable
|
(5 | ) | ||||||||||||||||||||||||||||||
Stock
for Recaf license
|
(400,000 | ) | (5 | ) | ||||||||||||||||||||||||||||
Warrants
exercised-Dec 2007
|
100,000 | 1 | 43,999 | 44,000 | ||||||||||||||||||||||||||||
Issuable
common stock from Private Placement
|
1,190,000 | 6 | 172,494 | 172,500 | ||||||||||||||||||||||||||||
Net
loss for the year
|
(2,728,269 | ) | (2,728,269 | ) | ||||||||||||||||||||||||||||
Balance,
Dec. 2007
|
48,444,442 | 262 | 1,190,000 | 6 | 19,323,715 | (19,585,032 | ) | (261,049 | ) |
Deficit
Accumulated
|
||||||||||||||||||||||||||||||||
Common
Stock
|
Additional
|
During
the
|
||||||||||||||||||||||||||||||
Common
Stock
|
Issuable
|
Paid-in
|
Subscription
|
Development
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Receivable
|
Stage
|
Total
|
|||||||||||||||||||||||||
Issuance
of common stock for services:
|
||||||||||||||||||||||||||||||||
Feb
2008
|
278,846 | 1 | 39,999 | 40,000 | ||||||||||||||||||||||||||||
March
2008
|
90,500 | 1 | 74,999 | 75,000 | ||||||||||||||||||||||||||||
May
2008
|
568,170 | 2 | 112,498 | 112,500 | ||||||||||||||||||||||||||||
Issuable
common stock from Private Placement and warrants
|
1,700,000 | 9 | 254,991 | 255,000 | ||||||||||||||||||||||||||||
Issuance
of common stock from Private Placement
|
1,700,000 | 9 | (1,190,000 | ) | (6 | ) | 82,497 | 82,500 | ||||||||||||||||||||||||
Issuance
of common stock issuable from Private Placement
|
1,700,000 | 9 | (1,700,000 | ) | (9 | ) | ||||||||||||||||||||||||||
Issuable
common stock pursuant to consulting agreements
|
2,250,000 | 11 | 674,989 | 675,000 | ||||||||||||||||||||||||||||
Issuable
common stock to Directors
|
600,000 | 3 | 179,997 | 180,000 | ||||||||||||||||||||||||||||
Net
loss for period
|
(954,094)
|
(954,094 | ) | |||||||||||||||||||||||||||||
Balance,
June 30, 2008
|
52,781,958 | 284 | 2,850,000 | 14 | $ | 20,743,685 |
(20,539,126)
|
$ | 204,857 |
2008
|
2007
|
Cumulative
During the Development Stage
|
||||||||||
Cash
Flows from Operating Activities
|
||||||||||||
Net
loss for period
|
$ | (954,094 | ) | $ | (546,586 | ) | $ | (20,539,126 | ) | |||
Adjustments
to reconcile net loss to net cash used in operating
activities
|
||||||||||||
Depreciation
expense
|
426 | 509 | 3,388 | |||||||||
Issuance
of common stock for services and expenses
|
1,082,500 | 285,000 | 15,750,636 | |||||||||
Warrants
issued for consulting services
|
- | - | 2,600,387 | |||||||||
Stock
options issued for consulting services
|
212,734 | |||||||||||
Changes
in operating assets and liabilities
|
||||||||||||
Prepaid
expenses
|
(317,500 | ) | 135,200 | (427,500 | ) | |||||||
Amounts
due to outside management consultants
|
- | |||||||||||
Accounts
payable
|
(108,397 | ) | 29,391 | (390 | ) | |||||||
Accrued
interest payable
|
- | 36,294 | ||||||||||
Net
cash used in operating activities
|
(297,065 | ) | (96,497 | ) | (2,363,577 | ) | ||||||
Cash
Flows from Investing Activities
|
||||||||||||
Purchase
of computer equipment
|
- | - | (3,388 | ) | ||||||||
Net
cash used in investing activities
|
- | - | (3,388 | ) | ||||||||
Cash
Flows from Financing Activities
|
||||||||||||
Warrants
exercised
|
- | 749,000 | ||||||||||
Stock
options exercised
|
100,500 | |||||||||||
Issuance
of common stock for cash
|
337,500 | 980,250 | ||||||||||
Loan
proceeds
|
- | 615,000 | ||||||||||
Net
cash provided by financing activities
|
337,500 | - | 2,444,750 | |||||||||
Net
change in cash
|
40,435 | (96,497 | ) | 77,785 | ||||||||
Cash,
beginning of period
|
37,350 | 166,115 | ||||||||||
Cash,
end of period
|
$ | 77,785 | $ | 69,618 | $ | 77,785 | ||||||
Cash
paid for interest
|
$ | 12,000 | $ | 12,703 | $ | 24,703 | ||||||
Cash
paid for income taxes
|
$ | - | $ | - | $ | - | ||||||
Supplementary
information - Non-cash Transactions:
|
||||||||||||
Stock
subscriptions received
|
$ | - | $ | 330,000 | ||||||||
Note
payable converted to common stock
|
$ | - | $ | 58,658 | 350,457 |
ITEM
2.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OR PLAN OF
OPERATIONS
|
|
1.
|
pH
ranging from a strong acid level of 1.8 (stronger than stomach acid) to a
strong alkali level of 13.8. (the pH scale is calibrated from 1, highly
acidic, to 14, highly alkali);
|
|
2.
|
Enzymatic
action using protease, which targets the amino acid bonds, and
glycosidase, which targets the amino acid bonds, and glycosidase, which
targets the sugar molecules; and
|
|
3.
|
Temperatures
ranging from -196°C (cryopreservation) to +37°C (body
temperature).
|
·
|
Stem
cells (human)
|
·
|
Adult
skin fibroblast cells
|
·
|
Whole
blood cells
|
·
|
Heart
cells (cardiac myocites)
|
·
|
Blood
Platelet cells
|
·
|
Liver
cells (hepatocites)
|
·
|
Heart
tissue
|
·
|
Embryonic
skin fibroblast cells
|
·
|
Hela
(cancer) cells
|
·
|
Islet
cells (pancreatic)
|
·
|
Kidney
(KB and vero) cells
|
·
|
Stem
cells (mouse)
|
|
·
|
temperatures
ranging from -80° C to +37°
|
|
·
|
harsh
sterilizing radiation
|
|
·
|
254
nanometer wavelength
|
|
·
|
hydrogen
peroxide (H2O20
|
|
·
|
powerful
oxidant
|
|
·
|
serum
free culture media
|
|
·
|
food/growth/nutrients
factors (fetal bovine serum)
withheld
|
|
·
|
Interleukin
1 Beta, a standard agent for stimulating inflammation in cell
testing
|
|
·
|
All
of the above tests are also considered to cause
inflammation
|
|
·
|
Scientific
and technological capability;
|
|
·
|
Proprietary
know-how;
|
|
·
|
The
ability to develop and market products and
processes;
|
|
·
|
The
ability to obtain FDA or other required regulatory
approvals;
|
|
·
|
The
ability to manufacture products that meet applicable FDA requirements,
(i.e. FDA’s Quality System Regulations) see Governmental Regulation
section;
|
|
·
|
Access
to adequate capital;
|
|
·
|
The
ability to attract and retain qualified personnel;
and
|
|
·
|
The
availability of patent protection.
|
ITEM
3.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
|
ITEM
4.
|
CONTROLS
AND PROCEDURES
|
ITEM
1.
|
LEGAL
PROCEEDINGS
|
ITEM
1A.
|
RISK
FACTORS
|
ITEM
2.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS
|
ITEM
3.
|
DEFAULT
UPON SENIOR SECURITIES
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS
|
ITEM
5.
|
OTHER
INFORMATION
|
ITEM
6.
|
EXHIBITS
AND REPORTS ON FORM 8-K.
|
Ex.
#
|
Description
|
|
3(i).1
|
Certificate
of Incorporation filed as an exhibit to the Company's registration
statement on Form 10SB/A filed on July 24, 2001 and incorporated herein by
reference.
|
|
3(ii).1
|
By-Laws
filed as an exhibit to the Company's registration statement on Form 10SB/A
filed on July 24, 2001 and incorporated herein by
reference.
|
|
14.1
|
ProtoKinetix,
Inc. Code of Ethics filed as an exhibit to our annual report on Form
10-KSB filed on April 13, 2006.
|
|
Rule
13a-12(a)/15d-14(a) Certification of Chief Executive Officer and Chief
Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant
to Section 302 the Sarbanes-Oxley Act of 2002.
|
||
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to 18
U.S.C Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
|
Protokinetix,
Inc.
|
||
/s/ Ross L. Senior
|
||
By: Ross
L. Senior
|
||
Its: President,
CEO and CFO
|
||
Signatures
|
Title
|
Date
|
||
/s/Ross L.
Senior
|
Chief
Executive Officer, President, and
|
August
14, 2008
|
||
Ross
L. Senior
|
Chief
Financial Officer
|